Lipidor AB (Nasdaq First North:LIPI) today announced that the Company has signed an exclusive licensing agreement with Cannassure Therapeutics Ltd. (TASE:CSURE), an Israeli company specializing in...
Cannassure Therapeutics Ltd (TASE: CSURE) (“Cannassure”), an Israel based developer and producer of innovative medical cannabis products, announces today the successful completion of a feasibility study for...
Lipidor AB (Nasdaq First North:LIPI) today announces a positive outcome of the feasibility study into the development of topical medicinal cannabis products for the treatment of skin inflammations...